<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343274</url>
  </required_header>
  <id_info>
    <org_study_id>BLZ-100EA</org_study_id>
    <nct_id>NCT04343274</nct_id>
  </id_info>
  <brief_title>Expanded Access for BLZ-100 (Tozuleristide)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blaze Bioscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blaze Bioscience Inc.</source>
  <brief_summary>
    <textblock>
      This is the Blaze Bioscience expanded access program for its investigational drug&#xD;
      tozuleristide intended for patients with life-threatening diseases or conditions who have&#xD;
      exhausted approved treatment options and are unable to participate in a clinical trial&#xD;
      involving the investigational drug tozuleristide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Contact Information: A licensed treating physician may submit questions or requests on&#xD;
           behalf of a patient regarding expanded access to tozuleristide to be evaluated in&#xD;
           accordance with Blaze Bioscience company policies. Physician Expanded Access Requests&#xD;
           should be submitted in writing to expandedaccess@blazebioscience.com and include&#xD;
           &quot;Expanded Access Request&quot; in the subject.&#xD;
&#xD;
        2. Request Procedures:&#xD;
&#xD;
             1. General Criteria: Blaze Bioscience will evaluate and respond to each Expanded&#xD;
                Access Request individually and on a case-by-case basis. Criteria Blaze Bioscience&#xD;
                will use in its evaluation of whether to grant Expanded Access Request include:&#xD;
&#xD;
                  1. Adequate supply of the investigational drug tozuleristide must be available&#xD;
                     above and beyond the supply needed for Blaze Bioscience clinical trials;&#xD;
&#xD;
                  2. There is sufficient clinical data to identify an appropriate dose of the&#xD;
                     investigational drug;&#xD;
&#xD;
                  3. There is a good understanding of the patient's clinical situation and&#xD;
                     investigational drug proposed use for surgery including the proposed&#xD;
                     fluorescence detection device;&#xD;
&#xD;
                  4. All available therapeutic approaches for the patient's disease have been&#xD;
                     exhausted by the patient and their physicians;&#xD;
&#xD;
                  5. The investigational drug is considered an &quot;eligible investigational drug&quot;&#xD;
                     under Section 561(B)(2) of the FDCA at the time of the Expanded Access&#xD;
                     Request;&#xD;
&#xD;
                  6. Providing the investigational drug is compliant with all applicable rules and&#xD;
                     laws;&#xD;
&#xD;
                  7. Appropriate Institutional Review Board/Ethics Committee and FDA authorization&#xD;
                     requested expanded access has been obtained;&#xD;
&#xD;
                  8. Treating physician understands and is willing to be responsible for ensuring&#xD;
                     that the patient informed consent requirements are met; and&#xD;
&#xD;
                  9. Treating physician understands and is willing to be the holder of a treatment&#xD;
                     IND with FDA.&#xD;
&#xD;
             2. Timing of acknowledgement: Blaze Bioscience endeavors to acknowledge requests&#xD;
                within ten (10) business days of receipt of an Expanded Access Request.&#xD;
&#xD;
             3. Clinical trials: Blaze Bioscience lists its active clinical trials on&#xD;
                clinicaltrials.gov. Before granting an Expanded Access Request for tozuleristide,&#xD;
                written confirmation by the treating physician that the patient is not eligible for&#xD;
                an active Company clinical trial is needed prior to consideration of the Expanded&#xD;
                Access Request.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tozuleristide</intervention_name>
    <other_name>BLZ-100</other_name>
    <other_name>Tumor Paint</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing surgery for suspected or confirmed tumor&#xD;
&#xD;
          -  Not eligible for current clinical trials of tozuleristide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Blaze Bioscience Expanded Access</last_name>
    <phone>206-535-8144</phone>
    <email>expandedaccess@blazebioscience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blaze Bioscience Info</last_name>
    <email>info@blazebioscience.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

